| CAS: | 16611-84-0 | |
| 分子式: | C22H36O3 | |
| 分子量: | 348.52 | |
| 英文名称: |
| |
| 用途: | Anacardic Acid是一个有效的p300及p300/CBP相关因子 histone acetyltranferases的抑制剂,也具有抗细菌和抗微生物活性,抑制前列腺素合成,并抑制酪氨酸酶和脂肪氧合酶。心酸被发现是几种临床靶向酶的常见抑制剂,如NFKB激酶、组蛋白乙酰转移酶(HATS)、脂氧合酶(LOX-1)、黄嘌呤氧化酶、酪氨酸酶和尿素酶[4]。心酸也是tip60体外的一种有效抑制剂,它抑制tip60依赖的乙酰化和激活hela细胞中的atm蛋白激酶,并使细胞对辐射的细胞毒性作用敏感[2]。无氨酸能有效地防止H2O2引起的细胞损伤,因为在金属离子的存在下,它可以转化为活性氧、羟基自由基[4]。 |
| 货号 | 品牌 | 产品名称 | 规格 | 包装、参考价格 | |||||||||||||||||||||||||||||||||||||||||
| A793181 | MACKLIN | Anacardic Acid | 10mM in DMSO | 620元/1ml; | 咨询 | ||||||||||||||||||||||||||||||||||||||||
储存:-20°C | |||||||||||||||||||||||||||||||||||||||||||||
| A872494 | MACKLIN | Anacardic Acid | 分析对照品,98% | 416元/5mg; 1125元/25mg; | 咨询 | ||||||||||||||||||||||||||||||||||||||||
储存:-20℃ 状态:白色到米黄色粉末 | |||||||||||||||||||||||||||||||||||||||||||||
| A766762 | MACKLIN | Anacardic Acid | 97% | 3494元/100mg; | 咨询 | ||||||||||||||||||||||||||||||||||||||||
储存:-20℃ 状态:白色到米黄色粉末 | |||||||||||||||||||||||||||||||||||||||||||||
| 953754 | J&K | Ginkgolic Acid C15:0 | 98%, 来源于银杏 | 1000元/20MG; | 咨询 | ||||||||||||||||||||||||||||||||||||||||
基本信息
| |||||||||||||||||||||||||||||||||||||||||||||
| A7236 | Sigma-Aldrich | Anacardic acid | 1795.68元/5 MG; 5736.48元/25 MG; | 咨询 | |||||||||||||||||||||||||||||||||||||||||
产品说明 应用 漆树酸已:
包装 5, 25 mg in glass bottle 生化/生理作用 漆树酸是一种从腰果果壳中提取的天然生物活性化合物。它具有抗真菌、抗菌、抗白蚁和杀软体动物的活性。漆树酸作为一种治疗剂,可对抗肥胖、癌症、炎症疾病和氧化损伤。它作为各种酶的抑制剂,如脂氧合酶(LOX-1)、黄嘌呤氧化酶、核因子κ B (NFκB)激酶、酪氨酸酶和脲酶。 特点和优势 这种化合物是基因调控研究的特色产品。点击此处发现更多特色基因调控产品。在sigma.com/discover-bsm可了解更多关于生物活性小分子的其他研究领域。 基本信息
产品性质
安全信息
| |||||||||||||||||||||||||||||||||||||||||||||
| 172050 | Sigma-Aldrich | Anacardic Acid-CAS 16611-84-0-Calbiochem | The Anacardic Acid, also referenced under CAS 16611-84-0, modulates the biological activity of Anacardic. This small molecule/inhibitor is primarily used for Cell Structure applications. | 1763.65元/10 MG; | 咨询 | ||||||||||||||||||||||||||||||||||||||||
产品说明 一般描述 A cell-permeable ginkgolic acid (Cat. No. 345887) analog that inhibits protein SUMO (Cat. Nos. 662037, 662039, and 662042) modification (IC50 = 2.2 µM using RanGAP1-C2 as substrate) in an ATP-dependent manner by selectively targeting SUMO-activating enzyme E1 (Cat. Nos. 662073 and 662074) and interfering with E1-SUMO intermediate formation. Both anacardic acid and ginkgolic acid are shown to effectively decrease overall SUMOylation of 293T cellular proteins in a dose-dependent manner, while neither compound is effective in affecting overall cellular protein ubiquitination or histone H4K8 acetylation in 293T cultures, although anacardic acid is shown to inhibit p300 (Cat. No. 506200) and PCAF (Cat. No. 124026) histone acetyltransferase activities in cell-free acetylase assays (by 82% and 86%, respectively, at 10 µM). Also reported to inhibit the activity of prostaglandin synthase, tyrosinase, and lipoxygenase, as well as to enhance Aurora kinase A (Cat. No. 481413), but not Aurora kinase B, autophosphorylation and kinase activity by inducing conformation change and enhancing ATP binding. 包装 10 mg in Plastic ampoule 生化/生理作用 Target IC50: 5 µM against HAT; 8.5 µM against PCAF; 2.2 µM inhibiting protein SUMO modification using RanGAP1-C2 as substrate 警告 Toxicity: Standard Handling (A) 重悬 Following reconstitution aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C. 其他说明 Fukuda, I., et al. 2009. Chem. Biol.16, 133. 法律信息 Sold under license of U.S. Patent 7,332,629 and related patents. 基本信息
产品性质
安全信息
| |||||||||||||||||||||||||||||||||||||||||||||
| 05506 | Supelco | (15:0)-Anacardic acid | analytical standard | 4167.23元/10MG; | 咨询 | ||||||||||||||||||||||||||||||||||||||||
产品说明 一般描述 (15:0)-Anacardic acid is a mixture of salicylic acid analogues, comprising of a 15 carbon aliphatic side chain in various degrees of unsaturation. 生化/生理作用 漆树酸是 HAT(组蛋白乙酰转移酶)抑制剂。 包装 Bottomless glass bottle. Contents are inside inserted fused cone. 基本信息
产品性质
安全信息
| |||||||||||||||||||||||||||||||||||||||||||||
| 546922 | Fluorochem | 2-Hydroxy-6-pentadecylbenzoic acid | 98+% | 14300元/250mg; 35728元/1g; | 咨询 | ||||||||||||||||||||||||||||||||||||||||
基本信息
| |||||||||||||||||||||||||||||||||||||||||||||